2006

NGO Update

Jerald Hess  
*American University Washington College of Law*

Follow this and additional works at: [http://digitalcommons.wcl.american.edu/hrbrief](http://digitalcommons.wcl.american.edu/hrbrief)

Recommended Citation
OneWorld Health represents a possible future that is hopeful for human rights and the millions of people in need in the developing world.

On September 19, 2006, the John D. and Catherine T. MacArthur Foundation named Dr. Hale a 2006 MacArthur Fellow. MacArthur Fellowships are awarded to individuals who have developed original and creative ideas through which they can potentially make significant contributions to the world. The MacArthur Foundation through an unsolicited, meticulous review process chooses 25 to 30 Fellows each year. Each Fellow receives an unrestricted grant of $500,000 distributed over the course of five years. The MacArthur Foundation recognized Dr. Hale as a Pharmaceutical Entrepreneur for her creation of OneWorld Health and her significant contribution to medicine in developing countries. In addition to being named a MacArthur Fellow, Dr. Hale has also been selected as a 2006 Ashoka Senior Fellow for leading work in social innovation, as well as being selected Esquire Magazine’s Executive of the Year in 2005. The MacArthur Fellowship came only days after OneWorld Health achieved international attention for the approval of one of its most recent research projects. On September 8, 2006 the Drug Controller General of India approved Paromomycin Intramuscular Injection for the treatment of Visceral Leishmaniasis (VL). VL is the second most deadly parasitic disease in the world following malaria. The treatment for VL was approved less than three months after OneWorld Health submitted the drug’s application.

In the last decade the relationship between the pharmaceutical industry and the developing world has gained significant international attention, most of which has been negative. Dr. Hale and OneWorld Health illustrate a significant shift in the way people view the pharmaceutical industry. If a nonprofit business model can successfully deliver current and future medicine and medical technology to the developing world, the potential impact is immense. As scientists continue to develop new medicines, OneWorld Health represents an effort to decrease costs of production, OneWorld secures donated intellectual property and utilizes the scientific and manufacturing capacity of the developing world in order to deliver affordable and effective medicine where these resources are needed most.

On September 19, 2006, the John D. and Catherine T. MacArthur Foundation named Dr. Hale a 2006 MacArthur Fellow. MacArthur Fellowships are awarded to individuals who have developed original and creative ideas through which they can potentially make significant contributions to the world. The MacArthur Foundation through an unsolicited, meticulous review process chooses 25 to 30 Fellows each year. Each Fellow receives an unrestricted grant of $500,000 distributed over the course of five years. The MacArthur Foundation recognized Dr. Hale as a Pharmaceutical Entrepreneur for her creation of OneWorld Health and her significant contribution to medicine in developing countries. In addition to being named a MacArthur Fellow, Dr. Hale has also been selected as a 2006 Ashoka Senior Fellow for leading work in social innovation, as well as being selected Esquire Magazine’s Executive of the Year in 2005. The MacArthur Fellowship came only days after OneWorld Health achieved international attention for the approval of one of its most recent research projects. On September 8, 2006 the Drug Controller General of India approved Paromomycin Intramuscular Injection for the treatment of Visceral Leishmaniasis (VL). VL is the second most deadly parasitic disease in the world following malaria. The treatment for VL was approved less than three months after OneWorld Health submitted the drug’s application.

In the last decade the relationship between the pharmaceutical industry and the developing world has gained significant international attention, most of which has been negative. Dr. Hale and OneWorld Health illustrate a significant shift in the way people view the pharmaceutical industry. If a nonprofit business model can successfully deliver current and future medicine and medical technology to the developing world, the potential impact is immense. As scientists continue to develop new medicines, OneWorld Health represents an effort to decrease costs of production, OneWorld secures donated intellectual property and utilizes the scientific and manufacturing capacity of the developing world in order to deliver affordable and effective medicine where these resources are needed most.

On September 19, 2006, the John D. and Catherine T. MacArthur Foundation named Dr. Hale a 2006 MacArthur Fellow. MacArthur Fellowships are awarded to individuals who have developed original and creative ideas through which they can potentially make significant contributions to the world. The MacArthur Foundation through an unsolicited, meticulous review process chooses 25 to 30 Fellows each year. Each Fellow receives an unrestricted grant of $500,000 distributed over the course of five years. The MacArthur Foundation recognized Dr. Hale as a Pharmaceutical Entrepreneur for her creation of OneWorld Health and her significant contribution to medicine in developing countries. In addition to being named a MacArthur Fellow, Dr. Hale has also been selected as a 2006 Ashoka Senior Fellow for leading work in social innovation, as well as being selected Esquire Magazine’s Executive of the Year in 2005. The MacArthur Fellowship came only days after OneWorld Health achieved international attention for the approval of one of its most recent research projects. On September 8, 2006 the Drug Controller General of India approved Paromomycin Intramuscular Injection for the treatment of Visceral Leishmaniasis (VL). VL is the second most deadly parasitic disease in the world following malaria. The treatment for VL was approved less than three months after OneWorld Health submitted the drug’s application.

In the last decade the relationship between the pharmaceutical industry and the developing world has gained significant international attention, most of which has been negative. Dr. Hale and OneWorld Health illustrate a significant shift in the way people view the pharmaceutical industry. If a nonprofit business model can successfully deliver current and future medicine and medical technology to the developing world, the potential impact is immense. As scientists continue to develop new medicines, OneWorld Health represents an effort to decrease costs of production, OneWorld secures donated intellectual property and utilizes the scientific and manufacturing capacity of the developing world in order to deliver affordable and effective medicine where these resources are needed most.

On September 19, 2006, the John D. and Catherine T. MacArthur Foundation named Dr. Hale a 2006 MacArthur Fellow. MacArthur Fellowships are awarded to individuals who have developed original and creative ideas through which they can potentially make significant contributions to the world. The MacArthur Foundation through an unsolicited, meticulous review process chooses 25 to 30 Fellows each year. Each Fellow receives an unrestricted grant of $500,000 distributed over the course of five years. The MacArthur Foundation recognized Dr. Hale as a Pharmaceutical Entrepreneur for her creation of OneWorld Health and her significant contribution to medicine in developing countries. In addition to being named a MacArthur Fellow, Dr. Hale has also been selected as a 2006 Ashoka Senior Fellow for leading work in social innovation, as well as being selected Esquire Magazine’s Executive of the Year in 2005. The MacArthur Fellowship came only days after OneWorld Health achieved international attention for the approval of one of its most recent research projects. On September 8, 2006 the Drug Controller General of India approved Paromomycin Intramuscular Injection for the treatment of Visceral Leishmaniasis (VL). VL is the second most deadly parasitic disease in the world following malaria. The treatment for VL was approved less than three months after OneWorld Health submitted the drug’s application.

In the last decade the relationship between the pharmaceutical industry and the developing world has gained significant international attention, most of which has been negative. Dr. Hale and OneWorld Health illustrate a significant shift in the way people view the pharmaceutical industry. If a nonprofit business model can successfully deliver current and future medicine and medical technology to the developing world, the potential impact is immense. As scientists continue to develop new medicines, OneWorld Health represents an effort to decrease costs of production, OneWorld secures donated intellectual property and utilizes the scientific and manufacturing capacity of the developing world in order to deliver affordable and effective medicine where these resources are needed most.

On September 19, 2006, the John D. and Catherine T. MacArthur Foundation named Dr. Hale a 2006 MacArthur Fellow. MacArthur Fellowships are awarded to individuals who have developed original and creative ideas through which they can potentially make significant contributions to the world. The MacArthur Foundation through an unsolicited, meticulous review process chooses 25 to 30 Fellows each year. Each Fellow receives an unrestricted grant of $500,000 distributed over the course of five years. The MacArthur Foundation recognized Dr. Hale as a Pharmaceutical Entrepreneur for her creation of OneWorld Health and her significant contribution to medicine in developing countries. In addition to being named a MacArthur Fellow, Dr. Hale has also been selected as a 2006 Ashoka Senior Fellow for leading work in social innovation, as well as being selected Esquire Magazine’s Executive of the Year in 2005. The MacArthur Fellowship came only days after OneWorld Health achieved international attention for the approval of one of its most recent research projects. On September 8, 2006 the Drug Controller General of India approved Paromomycin Intramuscular Injection for the treatment of Visceral Leishmaniasis (VL). VL is the second most deadly parasitic disease in the world following malaria. The treatment for VL was approved less than three months after OneWorld Health submitted the drug’s application.

In the last decade the relationship between the pharmaceutical industry and the developing world has gained significant international attention, most of which has been negative. Dr. Hale and OneWorld Health illustrate a significant shift in the way people view the pharmaceutical industry. If a nonprofit business model can successfully deliver current and future medicine and medical technology to the developing world, the potential impact is immense. As scientists continue to develop new medicines, OneWorld Health represents an effort to decrease costs of production, OneWorld secures donated intellectual property and utilizes the scientific and manufacturing capacity of the developing world in order to deliver affordable and effective medicine where these resources are needed most.

On September 19, 2006, the John D. and Catherine T. MacArthur Foundation named Dr. Hale a 2006 MacArthur Fellow. MacArthur Fellowships are awarded to individuals who have developed original and creative ideas through which they can potentially make significant contributions to the world. The MacArthur Foundation through an unsolicited, meticulous review process chooses 25 to 30 Fellows each year. Each Fellow receives an unrestricted grant of $500,000 distributed over the course of five years. The MacArthur Foundation recognized Dr. Hale as a Pharmaceutical Entrepreneur for her creation of OneWorld Health and her significant contribution to medicine in developing countries. In addition to being named a MacArthur Fellow, Dr. Hale has also been selected as a 2006 Ashoka Senior Fellow for leading work in social innovation, as well as being selected Esquire Magazine’s Executive of the Year in 2005. The MacArthur Fellowship came only days after OneWorld Health achieved international attention for the approval of one of its most recent research projects. On September 8, 2006 the Drug Controller General of India approved Paromomycin Intramuscular Injection for the treatment of Visceral Leishmaniasis (VL). VL is the second most deadly parasitic disease in the world following malaria. The treatment for VL was approved less than three months after OneWorld Health submitted the drug’s application.

In the last decade the relationship between the pharmaceutical industry and the developing world has gained significant international attention, most of which has been negative. Dr. Hale and OneWorld Health illustrate a significant shift in the way people view the pharmaceutical industry. If a nonprofit business model can successfully deliver current and future medicine and medical technology to the developing world, the potential impact is immense. As scientists continue to develop new medicines, OneWorld Health represents an effort to decrease costs of production, OneWorld secures donated intellectual property and utilizes the scientific and manufacturing capacity of the developing world in order to deliver affordable and effective medicine where these resources are needed most.
NGO UPDATE

The ABF is an American NGO that was created primarily to serve as a fundraising mechanism for the ABFT. However, the ABF has also become an active restorative justice program. Each year Linda Biehl and colleagues travel the United States, sharing stories and teaching youth about restorative justice. The ABF also supports interns both in the United States and in South Africa. Linda Biehl views ABF’s work as facilitating restorative justice and educating America’s youth. The ABF works to teach American students the value of other cultures and listening skills. Through the ABF and the ABFT, Amy Biehl’s legacy continues. As South Africa continues to emerge as a new democracy, the NGOs create a setting for students in the U.S. and South Africa to learn about restorative justice and appreciate the lessons of other cultures.

Jerald Hess, a J.D. candidate at the Washington College of Law, covers the NGO Update for the Human Rights Brief.

HRB